Novartis Announces $12bn Avidity Biosciences Acquisition
Kirkland & Ellis is advising Avidity Biosciences with a brand new team, as Novartis plans to acquire the San Diego-based RNA therapeutics developer for $12bn.
Covington & Burling is advising Novartis on the transaction, which is due to complete in the first half of 2026.
Novartis will acquire Avidity's Antibody Oligonucleotide Conjugates (AOCs) platform for RNA therapeutics and three late-stage neuroscience programs for neuromuscular diseases.
No direct quotes available in the text.
Author's summary: Novartis acquires Avidity Biosciences for $12bn.